<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ESC Heart Fail</journal-id><journal-id journal-id-type="iso-abbrev">ESC Heart Fail</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2055-5822</journal-id><journal-id journal-id-type="publisher-id">EHF2</journal-id><journal-title-group><journal-title>ESC Heart Failure</journal-title></journal-title-group><issn pub-type="epub">2055-5822</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31647614</article-id><article-id pub-id-type="pmc">6989294</article-id><article-id pub-id-type="doi">10.1002/ehf2.12516</article-id><article-id pub-id-type="publisher-id">EHF212516</article-id><article-id pub-id-type="other">ESCHF-19-00036</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research Articles</subject></subj-group></article-categories><title-group><article-title>Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial</article-title><alt-title alt-title-type="right-running-head">IGT and albuminuria in chronic heart failure</alt-title><alt-title alt-title-type="left-running-head">K. Nochioka <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="ehf212516-cr-0001" contrib-type="author"><name><surname>Nochioka</surname><given-names>Kotaro</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ehf212516-cr-0002" contrib-type="author" corresp="yes"><name><surname>Sakata</surname><given-names>Yasuhiko</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0001">
<sup>1</sup>
</xref><address><email>sakatay@cardio.med.tohoku.ac.jp</email></address></contrib><contrib id="ehf212516-cr-0003" contrib-type="author"><name><surname>Miura</surname><given-names>Masanobu</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ehf212516-cr-0004" contrib-type="author"><name><surname>Shiroto</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ehf212516-cr-0005" contrib-type="author"><name><surname>Takahashi</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ehf212516-cr-0006" contrib-type="author"><name><surname>Saga</surname><given-names>Chie</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212516-cr-0007" contrib-type="author"><name><surname>Ikeno</surname><given-names>Yasuko</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212516-cr-0008" contrib-type="author"><name><surname>Shiba</surname><given-names>Nobuyuki</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ehf212516-cr-0009" contrib-type="author"><name><surname>Shinozaki</surname><given-names>Tsuyoshi</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ehf212516-cr-0010" contrib-type="author"><name><surname>Sugi</surname><given-names>Masafumi</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="ehf212516-cr-0011" contrib-type="author"><name><surname>Nakagawa</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="ehf212516-cr-0012" contrib-type="author"><name><surname>Komaru</surname><given-names>Tatsuya</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="ehf212516-cr-0013" contrib-type="author"><name><surname>Kato</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="ehf212516-cr-0014" contrib-type="author"><name><surname>Nozaki</surname><given-names>Eiji</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="ehf212516-cr-0015" contrib-type="author"><name><surname>Iwabuchi</surname><given-names>Kaoru</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="ehf212516-cr-0016" contrib-type="author"><name><surname>Hiramoto</surname><given-names>Tetsuya</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="ehf212516-cr-0017" contrib-type="author"><name><surname>Inoue</surname><given-names>Kanichi</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="ehf212516-cr-0018" contrib-type="author"><name><surname>Ohe</surname><given-names>Masatoshi</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="ehf212516-cr-0019" contrib-type="author"><name><surname>Tamaki</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="ehf212516-cr-0020" contrib-type="author"><name><surname>Tsuji</surname><given-names>Ichiro</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="ehf212516-cr-0021" contrib-type="author"><name><surname>Shimokawa</surname><given-names>Hiroaki</given-names></name><xref ref-type="aff" rid="ehf212516-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212516-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="ehf212516-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
<institution>Tohoku University Graduate School of Medicine</institution>
<named-content content-type="street">Seiryo&#x02010;machi 1&#x02013;1</named-content>
<city>Sendai</city>
<named-content content-type="country-part">Miyagi</named-content>
<postal-code>980&#x02013;8574</postal-code>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Evidence&#x02010;based Cardiovascular Medicine</named-content>
<institution>Tohoku University Graduate School of Medicine</institution>
<named-content content-type="country-part">Miyagi</named-content>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
<institution>International University of Health and Welfare Hospital</institution>
<city>Tochigi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division, Sendai Medical Center</named-content>
<institution>National Hospital Organization</institution>
<named-content content-type="country-part">Miyagi</named-content>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division, Iwaki City Medical Center</named-content>
<city>Fukushima</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
<institution>Iwate Prefectural Isawa Hospital</institution>
<city>Iwate</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
<institution>Tohoku Medical and Pharmaceutical University</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
<institution>Sendai Open Hospital</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
<institution>Iwate Prefectural Central Hospital</institution>
<city>Iwate</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division</named-content>
<institution>Osaki Citizen Hospital</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division</named-content>
<institution>Kurihara Central Hospital</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division</named-content>
<institution>Senen Rifu Hospital</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0013">
<label><sup>13</sup></label>
<named-content content-type="organisation-division">Cardiovascular Division</named-content>
<institution>Kojirakawa Shieido Hospital</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0014">
<label><sup>14</sup></label>
<named-content content-type="organisation-division">Cardiology Department</named-content>
<institution>Iwate Health Service Association</institution>
<city>Iwate</city>
<country country="JP">Japan</country>
</aff><aff id="ehf212516-aff-0015">
<label><sup>15</sup></label>
<named-content content-type="organisation-division">Division of Epidemiology, Department of Public Health and Forensic Medicine</named-content>
<institution>Tohoku University Graduate School of Medicine</institution>
<city>Miyagi</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence to: Yasuhiko Sakata, Department of Cardiovascular Medicine, Tohoku University School of Medicine, Seiryo&#x02010;machi 1&#x02010;1, Sendai, Miyagi 980&#x02010;8574, Japan. Tel: +81227177153; Fax: +81227177156. Email: <email>sakatay@cardio.med.tohoku.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>6</volume><issue>6</issue><issue-id pub-id-type="doi">10.1002/ehf2.v6.6</issue-id><fpage>1252</fpage><lpage>1261</lpage><history><date date-type="received"><day>16</day><month>2</month><year>2019</year></date><date date-type="rev-recd"><day>30</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 The Heart Failure Association of the European Society of Cardiology / John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. ESC Heart Failure published by John Wiley &#x00026; Sons Ltd on behalf of the European Society of Cardiology.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:EHF2-6-1252.pdf"/><abstract><title>Abstract</title><sec id="ehf212516-sec-0001"><title>Aims</title><p>The study aims to evaluate the prognostic significance of impaired glucose tolerance (IGT) with reference to albuminuria in patients with chronic heart failure (CHF).</p></sec><sec id="ehf212516-sec-0002"><title>Methods and results</title><p>We examined 535 CHF patients (mean 66&#x02009;years, women 25%) in the control arm of our SUPPORT trial, in which we examined additive impact of olmesartan in hypertensive patients with symptomatic CHF treated with &#x003b2;&#x02010;blockers and/or angiotensin&#x02010;converting enzyme inhibitors. We examined the association between glycaemic abnormality (assessed by 75&#x02009;g of oral glucose tolerance test) and albuminuria for a composite outcome of all&#x02010;cause death, myocardial infarction, stroke, and HF hospitalization. IGT patients (<italic>N</italic>&#x02009;=&#x02009;113, mean 67.2&#x02009;years) were older and more frequently treated with &#x003b2;&#x02010;blockers compared with those with normal glucose regulation (<italic>N</italic>&#x02009;=&#x02009;142, mean 64.0&#x02009;years) and those with diabetes mellitus (<italic>N</italic>&#x02009;=&#x02009;280, mean 65.7&#x02009;years). Multivariable Cox proportional hazard models revealed that, as compared with normal glucose regulation (NGR), IGT was associated with increased risk of the outcome when complicated by albuminuria [hazard ratio (HR) 2.25; 95% confidence interval (CI) 1.14&#x02013;4.42; <italic>P</italic>&#x02009;=&#x02009;0.019] but not when uncomplicated by albuminuria (HR 0.76; 95% CI 0.35&#x02013;1.60, <italic>P</italic>&#x02009;=&#x02009;0.47) (<italic>P</italic> for interaction&#x02009;=&#x02009;0.041). This was also the case for diabetes mellitus and albuminuria (HR 2.06; 95% CI 1.17&#x02013;3.61; <italic>P</italic>&#x02009;=&#x02009;0.012). Among IGT patients without albuminuria, 21 (29%) developed albuminuria at 1&#x02010;year visit, which was again associated with poor prognosis (HR 7.36; 95% CI 1.39&#x02013;38.98, <italic>P</italic>&#x02009;=&#x02009;0.019).</p></sec><sec id="ehf212516-sec-0003"><title>Conclusions</title><p>These results indicate that IGT is associated with poor prognosis when complicated by albuminuria in CHF patients, demonstrating the importance of combined early stages of glucose intolerance and renal dysfunction in the management of CHF.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ehf212516-kwd-0001">Chronic heart failure</kwd><kwd id="ehf212516-kwd-0002">Impaired glucose tolerance</kwd><kwd id="ehf212516-kwd-0003">Diabetes mellitus</kwd><kwd id="ehf212516-kwd-0004">Albuminuria</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Ministry of Health, Labour and Welfare, Japan </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003478</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Ministry of Education, Culture, Sports, Science and Technology </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001700</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="10"/><word-count count="3709"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.5 mode:remove_FC converted:29.01.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ehf212516-cit-0000">
<string-name>
<surname>Nochioka</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sakata</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Miura</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Shiroto</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Saga</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Ikeno</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Shiba</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Shinozaki</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Sugi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Komaru</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kato</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Nozaki</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Iwabuchi</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Hiramoto</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ohe</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tamaki</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tsuji</surname>, <given-names>I.</given-names>
</string-name>, and <string-name>
<surname>Shimokawa</surname>, <given-names>H.</given-names>
</string-name> (<year>2019</year>) <article-title>Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial</article-title>. <source xml:lang="en">ESC Heart Failure</source>, <volume>6</volume>: <fpage>1252</fpage>&#x02013;<lpage>1261</lpage>. <pub-id pub-id-type="doi">10.1002/ehf2.12516</pub-id>.</mixed-citation>
</p></notes></front><body id="ehf212516-body-0001"><sec id="ehf212516-sec-0004"><label>1</label><title>Introduction</title><p>Glucose regulation abnormalities, including impaired glucose tolerance (IGT), are commonly noted in non&#x02010;diabetic patients with chronic heart failure (CHF).<xref rid="ehf212516-bib-0001" ref-type="ref">1</xref>, <xref rid="ehf212516-bib-0002" ref-type="ref">2</xref>, <xref rid="ehf212516-bib-0003" ref-type="ref">3</xref>, <xref rid="ehf212516-bib-0004" ref-type="ref">4</xref>, <xref rid="ehf212516-bib-0005" ref-type="ref">5</xref> However, it remains unknown whether IGT itself is associated with poor prognosis, although a previous study suggested the correlation between IGT and HF severity.<xref rid="ehf212516-bib-0006" ref-type="ref">6</xref> Furthermore, IGT is usually assessed by baseline serum glucose,<xref rid="ehf212516-bib-0004" ref-type="ref">4</xref>, <xref rid="ehf212516-bib-0007" ref-type="ref">7</xref> insulin,<xref rid="ehf212516-bib-0006" ref-type="ref">6</xref> and haemoglobin A1c (HbA1c) levels<xref rid="ehf212516-bib-0008" ref-type="ref">8</xref> but not necessarily by oral glucose tolerance test (OGTT), which has advantages for accurate assessment of glucose regulation.<xref rid="ehf212516-bib-0008" ref-type="ref">8</xref>
</p><p>Accumulating evidence also indicates that albuminuria is associated with insulin resistance in patients with Types I<xref rid="ehf212516-bib-0009" ref-type="ref">9</xref> and II<xref rid="ehf212516-bib-0010" ref-type="ref">10</xref> diabetes mellitus (DM) as well as in non&#x02010;DM subjects,<xref rid="ehf212516-bib-0011" ref-type="ref">11</xref> suggesting that it is also the case in patients with IGT. However, it is still unclear whether IGT contributes to the development for albuminuria. This issue is clinically important in the management of CHF patients with IGT, because we found that not only macroalbuminuria but also microalbuminuria is significantly associated with increased mortality in CHF patients.<xref rid="ehf212516-bib-0012" ref-type="ref">12</xref> Furthermore, it has been recently shown that in Type I DM patients, myocardial deformation assessed by echocardiography was primarily associated with the presence of albuminuria,<xref rid="ehf212516-bib-0013" ref-type="ref">13</xref> suggesting that combination of abnormalities of glucose regulation and renal function may impair cardiac function in CHF patients. However, the prognostic value of combined IGT and albuminuria remains to be examined. In the present study, we thus aimed to evaluate the prognostic significance of IGT in relation with albuminuria in CHF patients, as a subanalysis study of our SUPPORT (supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan) trial.<xref rid="ehf212516-bib-0015" ref-type="ref">15</xref>, <xref rid="ehf212516-bib-0016" ref-type="ref">16</xref>
</p></sec><sec id="ehf212516-sec-0005"><label>2</label><title>Methods</title><sec id="ehf212516-sec-0006"><label>2.1</label><title>Study subjects</title><p>The present study is a post hoc, exploratory analysis, using the dataset of our SUPPORT trial.<xref rid="ehf212516-bib-0015" ref-type="ref">15</xref>, <xref rid="ehf212516-bib-0016" ref-type="ref">16</xref> The trial demonstrated that additive use of olmesartan did not improve clinical outcomes and that addition of olmesartan to the combination therapy with angiotensin&#x02010;converting enzyme inhibitors and &#x003b2;&#x02010;blockers was associated with increased adverse cardiac events in CHF patients.<xref rid="ehf212516-bib-0014" ref-type="ref">14</xref> Thus, among 1147 patients of our SUPPORT trial, we enrolled 569 patients in the control arm in the present study. Of the 569 patients enrolled, we excluded 19 patients with impaired fasting glucose and finally enrolled 142 with normal glucose regulation (NGR), 113 with IGT, 280 with DM (277 known DM and three newly diagnosed DM) (<italic>Figure</italic>
<xref rid="ehf212516-fig-0001" ref-type="fig">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="ehf212516-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study diagram. DM, diabetes mellitus; HbA1c, haemoglobin A1c; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGR, normal glucose regulation; OGTT, oral glucose tolerance test.</p></caption><graphic id="nlm-graphic-1" xlink:href="EHF2-6-1252-g001"/></fig></sec><sec id="ehf212516-sec-0007"><label>2.2</label><title>The SUPPORT trial</title><p>The SUPPORT trial (NCT00417222) was a randomized clinical trial that evaluated the efficacy and safety of olmesartan in stable CHF patients with a history of hypertension who had been treated with angiotensin&#x02010;converting enzyme inhibitors and/or &#x003b2;&#x02010;blockers or both at enrolment.<xref rid="ehf212516-bib-0014" ref-type="ref">14</xref>, <xref rid="ehf212516-bib-0015" ref-type="ref">15</xref> In the SUPPORT trial, patients were eligible if they met all the following criteria: (i) New York Heart Association (NYHA) Classes II to IV CHF, (ii) history of hypertension or treated with anti&#x02010;hypertensive medications, (iii) aged 20 to &#x0003c;80&#x02009;years, (iv) stable with angiotensin&#x02010;converting enzyme inhibitors and/or &#x003b2;&#x02010;blockers, and (v) not treated with angiotensin II receptor blockers. Exclusion criteria were (i) patients with renal dysfunction (serum creatinine &#x02265;3.0&#x02009;mg/dL) or those who were under chronic haemodialysis, (ii) drug hypersensitivity to olmesartan, (iii) severe liver dysfunction, (iv) history of angioedema, (v) history of malignant tumour or life&#x02010;threatening illness of poor prognosis, (vi) pregnant or possibly pregnant patients, (vii) cardiovascular surgery within 6&#x02009;months prior to the date of the entry, (viii) acute myocardial infarction within 6&#x02009;months prior to the date of the entry, and (ix) percutaneous coronary intervention with or without stent implantation within 6&#x02009;months prior to the date of the entry.<xref rid="ehf212516-bib-0014" ref-type="ref">14</xref>, <xref rid="ehf212516-bib-0015" ref-type="ref">15</xref>
</p><p>The trial was approved by institutional review boards at each institution, and all participants provided written informed consent. The trial was conducted according to the Declaration of Helsinki. The primary objective of the trial was to examine whether an additive treatment with an angiotensin II receptor blocker, olmesartan, would reduce the mortality and morbidity of chronic HF patients with a history of hypertension. Between October 2006 and March 2010, a total of 1147 CHF patients with a history of hypertension were assigned to either the olmesartan or the control group (standard care), according to a 1:1 ratio of olmesartan to control and were followed up until the study ended on 31 March 2013.</p></sec><sec id="ehf212516-sec-0008"><label>2.3</label><title>Definitions of impaired glucose tolerance, diabetes mellitus, and albuminuria</title><p>In the SUPPORT trial, patients without known DM underwent a standardized procedure of 75&#x02009;g of OGTT twice at enrolment [median (IQR) 5 (0&#x02013;33) days from randomization] and 1&#x02010;year follow&#x02010;up visit [median (IQR) 364 (339&#x02013;399) days after randomization] (<italic>Figure</italic>
<xref rid="ehf212516-fig-0001" ref-type="fig">1</xref>).<xref rid="ehf212516-bib-0016" ref-type="ref">16</xref> The abnormalities in glucose tolerance were defined according to the 2006 WHO criteria<xref rid="ehf212516-bib-0008" ref-type="ref">8</xref>; newly diagnosed DM as fasting plasma glucose &#x02265;126&#x02009;mg/dL (7.0&#x02009;mmol/L) or 2&#x02009;h plasma glucose &#x02265;200&#x02009;mg/dL (11.1&#x02009;mmol/L); IGT as fasting plasma glucose &#x0003c;126&#x02009;mg/dL (7.0&#x02009;mmol/L) and 2&#x02009;h plasma glucose &#x02265;140&#x02009;mg/dL but &#x0003c;200&#x02009;mg/dL (7.8 and 11.1&#x02009;mmol/L); impaired fasting glucose as fasting plasma glucose 110&#x02013;125&#x02009;mg/dL (6.1&#x02013;6.9&#x02009;mmol/L) and 2&#x02009;h plasma glucose &#x0003c;140&#x02009;mg/dL (7.8&#x02009;mmol/L). In the morning after a 9&#x02009;h fast, blood and urine samples were collected at each participating site. Blood samples were centrifuged within 30&#x02009;min at 4&#x000b0;C and were stored at &#x02212;20&#x000b0;C until assay. Urine samples were stored at 4&#x000b0;C until assay. Urine and blood samples were measured in a central laboratory (SRL, Tokyo, Japan), and urinary albumin&#x02010;to&#x02010;creatinine ratio (UACR) was calculated to compensate for variations in urine concentration in spot&#x02010;check samples. Albuminuria was defined as UACR &#x0003e;30&#x02009;mg/g to describe urine albumin levels not detected by a dipstick test.<xref rid="ehf212516-bib-0017" ref-type="ref">17</xref>
</p></sec><sec id="ehf212516-sec-0009"><label>2.4</label><title>Outcome</title><p>The study outcome was a composite of all&#x02010;cause death, non&#x02010;fatal myocardial infraction (MI), non&#x02010;fatal stroke, and hospitalization for worsening HF, which was identical to the SUPPORT trial.<xref rid="ehf212516-bib-0015" ref-type="ref">15</xref>, <xref rid="ehf212516-bib-0016" ref-type="ref">16</xref> All&#x02010;cause death was adjudicated by the death certificate and/or the medical records. The definitions of MI and stroke were based on the 2001 ACC key data elements and definitions.<xref rid="ehf212516-bib-0018" ref-type="ref">18</xref> A hospitalization for worsening HF was defined as an admission to a hospital necessitated by HF and primarily for its treatment or when HF became a major component of the patient's hospitalization.<xref rid="ehf212516-bib-0019" ref-type="ref">19</xref> A patient hospitalized for HF had to show signs and symptoms of worsening HF and require treatment with intravenous diuretics. Evidence of worsening HF included at least one of the following items: increasing dyspnoea on exertion, orthopnoea, nocturnal dyspnoea, pulmonary oedema, increasing peripheral oedema, increasing fatigue or decreasing exercise tolerance, renal hypoperfusion (e.g. worsening renal function), raised jugular venous pressure, and radiological signs of HF.<xref rid="ehf212516-bib-0019" ref-type="ref">19</xref> The independent events committee adjudicated all events for all&#x02010;cause death, non&#x02010;fatal MI, non&#x02010;fatal stroke, and hospitalization for worsening HF in a blinded fashion (SI, NI, and YM) in the SUPPORT trial.</p></sec><sec id="ehf212516-sec-0010"><label>2.5</label><title>Statistical methods</title><p>Clinical characteristics are described stratified by NGR, IGT, and DM. For comparing two groups, we used <italic>t</italic>&#x02010;test for normally distributed and Wilcoxon rank sum for non&#x02010;normally distributed data. For three or more groups, we used ANOVA for normally distributed and Kruskal&#x02013;Wallis for non&#x02010;normally distributed data. We examined determinants of albuminuria or IGT by multivariable logistic regression models with comparison of backward and forward selection methods considering the following variables at baseline as candidate: IGT (for the determinant of albuminuria), diabetes, albuminuria (for the determinant of IGT), age, sex, NYHA class, systolic and diastolic blood pressure (BP), heart rate, body mass index (BMI), smoking, ischaemic aetiology, history of HF hospitalization, atrial fibrillation, history of cancer, haemoglobin, estimated glomerular filtration rate, left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI), and brain natriuretic peptide (BNP). The final model was determined by the lowest value of Akaike information criterion. Event rates (per 1000 person&#x02010;years) were calculated for the composite of all&#x02010;cause death, non&#x02010;fatal MI, non&#x02010;fatal stroke, and hospitalization for worsening HF. Event rates were analysed with the exact probability test. For time to first event analysis, we plotted Kaplan&#x02013;Meier survival curves and employed multivariable Cox proportional hazard models adjusted for age, sex, ischaemic aetiology, NYHA functional class, systolic BP, heart rate, BMI, LVEF, history of HF hospitalization, and BNP.<xref rid="ehf212516-bib-0020" ref-type="ref">20</xref>, <xref rid="ehf212516-bib-0021" ref-type="ref">21</xref> We compared the risk between NGR and DM patients, without considering the presence or absence of albuminuria. Then, we examined the risk of DM considering the presence or absence of albuminuria, where NGR without albuminuria served as a reference. We also assessed the prognostic impact of combined glycaemic status and albuminuria stratified by baseline LVEF (&#x02265;50%, preserved; &#x02265;40 to &#x0003c;50%, mid&#x02010;range; and&#x02009;&#x0003c;&#x02009;40%, reduced).</p><p>To estimate the survival probabilities in unbiased way, we performed landmark analysis stratified by status of albuminuria at 1&#x02010;year visit evaluated by second urinalysis, setting date at 1&#x02010;year visit as observation Time 0.<xref rid="ehf212516-bib-0022" ref-type="ref">22</xref> A two&#x02010;sided <italic>P</italic> value of &#x0003c;0.05 was considered to be statistically significant. All analyses were performed with STATA 15 (College Station, TX).</p></sec></sec><sec id="ehf212516-sec-0011"><label>3</label><title>Results</title><sec id="ehf212516-sec-0012"><label>3.1</label><title>Baseline characteristics</title><p>Of 535 patients, the mean age was 65.6&#x02009;&#x000b1;&#x02009;10.0&#x02009;years, 25% were women, 93% had NYHA Class II, and 82% LVEF&#x02009;&#x0003e;&#x02009;40% (<italic>Table</italic>
<xref rid="ehf212516-tbl-0001" ref-type="table">1</xref>). The median (IQR) BNP level was 78.2 (38&#x02013;174) pg/mL. Median (IQR) HbA1c levels (%) were 5.7 (5.6, 5.9) in NGR, 5.8 (5.7, 6.1) in IGT, and 6.6 (6.1, 7.5) % in DM (<italic>Table</italic>
<xref rid="ehf212516-tbl-0001" ref-type="table">1</xref>). Patients with IGT, as compared with those with NGR and DM, were older and more likely to be treated with &#x003b2;&#x02010;blockers (<italic>Table</italic>
<xref rid="ehf212516-tbl-0001" ref-type="table">1</xref>). Median (IQR) UACR levels (mg/g) were 12.6 (6.2, 42.9) in NGR, 14.9 (8.7, 46.1) in IGT, and 26.8 (10.9, 93.0) in DM (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Albuminuria was noted in 47 (33%), 41 (36%), and 134 (48%) in NGR, IGT, and diabetes, respectively (<italic>P</italic>&#x02009;=&#x02009;0.007) (<italic>Table</italic>
<xref rid="ehf212516-tbl-0001" ref-type="table">1</xref> and Supporting Information, <italic>Table</italic>
<xref rid="ehf212516-supitem-0001" ref-type="supplementary-material">S1</xref>). Patients with DM and albuminuria had higher UACR [median (IQR): 103.0 (53.0, 294.0)] than those with IGT and albuminuria [77.5 (45.8, 165.0), <italic>P</italic>&#x02009;=&#x02009;0.11] (Supporting Information, <italic>Table</italic>
<xref rid="ehf212516-supitem-0001" ref-type="supplementary-material">S1</xref>). Across the categories, patients with albuminuria had higher prevalence of atrial fibrillation, larger left atrial dimension, and higher BNP levels.</p><table-wrap id="ehf212516-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="char" valign="bottom" rowspan="1" colspan="1">Overall (<italic>N</italic>&#x02009;=&#x02009;535)</th><th align="char" valign="bottom" rowspan="1" colspan="1">NGR (<italic>N</italic>&#x02009;=&#x02009;142)</th><th align="char" valign="bottom" rowspan="1" colspan="1">IGT (<italic>N</italic>&#x02009;=&#x02009;113)</th><th align="char" valign="bottom" rowspan="1" colspan="1">DM (<italic>N</italic>&#x02009;=&#x02009;280)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1">65.6&#x02009;&#x000b1;&#x02009;10.0</td><td align="center" valign="top" rowspan="1" colspan="1">64.0&#x02009;&#x000b1;&#x02009;11.8</td><td align="center" valign="top" rowspan="1" colspan="1">67.2&#x02009;&#x000b1;&#x02009;8.0<xref ref-type="fn" rid="ehf212516-note-0003">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">65.7&#x02009;&#x000b1;&#x02009;9.7</td><td align="char" valign="top" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Women, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">136 (25%)</td><td align="char" valign="top" rowspan="1" colspan="1">41 (29%)</td><td align="char" valign="top" rowspan="1" colspan="1">34 (30%)</td><td align="char" valign="top" rowspan="1" colspan="1">61 (22%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NYHA, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.37</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">II</td><td align="char" valign="top" rowspan="1" colspan="1">499 (93%)</td><td align="char" valign="top" rowspan="1" colspan="1">130 (92%)</td><td align="char" valign="top" rowspan="1" colspan="1">105 (93%)</td><td align="char" valign="top" rowspan="1" colspan="1">264 (95%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III</td><td align="char" valign="top" rowspan="1" colspan="1">33 (6%)</td><td align="char" valign="top" rowspan="1" colspan="1">12 (9%)</td><td align="char" valign="top" rowspan="1" colspan="1">8 (7%)</td><td align="char" valign="top" rowspan="1" colspan="1">13 (5%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systolic BP, mmHg</td><td align="center" valign="top" rowspan="1" colspan="1">127&#x02009;&#x000b1;&#x02009;18</td><td align="center" valign="top" rowspan="1" colspan="1">124&#x02009;&#x000b1;&#x02009;18</td><td align="center" valign="top" rowspan="1" colspan="1">129&#x02009;&#x000b1;&#x02009;19<xref ref-type="fn" rid="ehf212516-note-0003">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">128&#x02009;&#x000b1;&#x02009;18</td><td align="char" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diastolic BP, mmHg</td><td align="center" valign="top" rowspan="1" colspan="1">74&#x02009;&#x000b1;&#x02009;12</td><td align="center" valign="top" rowspan="1" colspan="1">73&#x02009;&#x000b1;&#x02009;11</td><td align="center" valign="top" rowspan="1" colspan="1">75&#x02009;&#x000b1;&#x02009;11</td><td align="center" valign="top" rowspan="1" colspan="1">74&#x02009;&#x000b1;&#x02009;12</td><td align="char" valign="top" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart rate, bpm</td><td align="center" valign="top" rowspan="1" colspan="1">71&#x02009;&#x000b1;&#x02009;15</td><td align="center" valign="top" rowspan="1" colspan="1">71&#x02009;&#x000b1;&#x02009;14</td><td align="center" valign="top" rowspan="1" colspan="1">71&#x02009;&#x000b1;&#x02009;14</td><td align="center" valign="top" rowspan="1" colspan="1">72&#x02009;&#x000b1;&#x02009;15</td><td align="char" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">24.6&#x02009;&#x000b1;&#x02009;4.1</td><td align="center" valign="top" rowspan="1" colspan="1">23.7&#x02009;&#x000b1;&#x02009;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">24.3&#x02009;&#x000b1;&#x02009;3.7<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">25.3&#x02009;&#x000b1;&#x02009;4.3</td><td align="char" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking (past or current), <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">272 (48%)</td><td align="char" valign="top" rowspan="1" colspan="1">74 (52%)</td><td align="char" valign="top" rowspan="1" colspan="1">51 (45%)</td><td align="char" valign="top" rowspan="1" colspan="1">147 (53%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ischaemic heart disease, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">249 (47%)</td><td align="char" valign="top" rowspan="1" colspan="1">47 (33%)</td><td align="char" valign="top" rowspan="1" colspan="1">47 (42%)<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">155 (55%)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of HF hospitalization, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">269 (50%)</td><td align="char" valign="top" rowspan="1" colspan="1">69 (49%)</td><td align="char" valign="top" rowspan="1" colspan="1">59 (52%)</td><td align="char" valign="top" rowspan="1" colspan="1">141 (50%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Atrial fibrillation, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">226 (42%)</td><td align="char" valign="top" rowspan="1" colspan="1">64 (45%)</td><td align="char" valign="top" rowspan="1" colspan="1">52 (46%)</td><td align="char" valign="top" rowspan="1" colspan="1">110 (39%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancer, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">59 (11%)</td><td align="char" valign="top" rowspan="1" colspan="1">19 (13%)</td><td align="char" valign="top" rowspan="1" colspan="1">10 (9%)</td><td align="char" valign="top" rowspan="1" colspan="1">30 (11%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LVEF, %</td><td align="center" valign="top" rowspan="1" colspan="1">53.7&#x02009;&#x000b1;&#x02009;14.5</td><td align="center" valign="top" rowspan="1" colspan="1">53.9&#x02009;&#x000b1;&#x02009;15.0</td><td align="center" valign="top" rowspan="1" colspan="1">50.9&#x02009;&#x000b1;&#x02009;14.8<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">54.7&#x02009;&#x000b1;&#x02009;14.1</td><td align="char" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LVEF categories</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.015</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">EF &#x02265;50%, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">310 (62%)</td><td align="char" valign="top" rowspan="1" colspan="1">85 (60%)</td><td align="char" valign="top" rowspan="1" colspan="1">60 (53%)</td><td align="char" valign="top" rowspan="1" colspan="1">184 (66%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">EF 40&#x02013;49%, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">110 (21%)</td><td align="char" valign="top" rowspan="1" colspan="1">35 (25%)</td><td align="char" valign="top" rowspan="1" colspan="1">21 (19%)</td><td align="char" valign="top" rowspan="1" colspan="1">54 (19%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">EF&#x02009;&#x0003c;&#x02009;40%, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">96 (18%)</td><td align="char" valign="top" rowspan="1" colspan="1">22 (16%)</td><td align="char" valign="top" rowspan="1" colspan="1">32 (28%)</td><td align="char" valign="top" rowspan="1" colspan="1">42 (15%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LV mass index, g/m<sup>2</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">137.0&#x02009;&#x000b1;&#x02009;43.8</td><td align="center" valign="top" rowspan="1" colspan="1">141.4&#x02009;&#x000b1;&#x02009;47.0</td><td align="center" valign="top" rowspan="1" colspan="1">143.6&#x02009;&#x000b1;&#x02009;44.1<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">132.0&#x02009;&#x000b1;&#x02009;41.3</td><td align="char" valign="top" rowspan="1" colspan="1">0.024</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">LV geometry</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Normal LV, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">35 (7%)</td><td align="char" valign="top" rowspan="1" colspan="1">9 (6%)</td><td align="char" valign="top" rowspan="1" colspan="1">8 (7%)</td><td align="char" valign="top" rowspan="1" colspan="1">18 (7%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Eccentric LVH, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">216 (41%)</td><td align="char" valign="top" rowspan="1" colspan="1">56 (39%)</td><td align="char" valign="top" rowspan="1" colspan="1">47 (43%)</td><td align="char" valign="top" rowspan="1" colspan="1">113 (41%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.84</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Concentric LV remodelling, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (3%)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (2%)</td><td align="char" valign="top" rowspan="1" colspan="1">0</td><td align="char" valign="top" rowspan="1" colspan="1">11 (4%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Concentric LVH, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">134 (25%)</td><td align="char" valign="top" rowspan="1" colspan="1">33 (23%)</td><td align="char" valign="top" rowspan="1" colspan="1">24 (21%)</td><td align="char" valign="top" rowspan="1" colspan="1">77 (28%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LA dimension, mm</td><td align="center" valign="top" rowspan="1" colspan="1">43.0&#x02009;&#x000b1;&#x02009;8.6</td><td align="center" valign="top" rowspan="1" colspan="1">42.6&#x02009;&#x000b1;&#x02009;9.4</td><td align="center" valign="top" rowspan="1" colspan="1">43.6&#x02009;&#x000b1;&#x02009;8.4</td><td align="center" valign="top" rowspan="1" colspan="1">43.0&#x02009;&#x000b1;&#x02009;8.1</td><td align="char" valign="top" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">E/A ratio</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x02009;&#x000b1;&#x02009;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.9&#x02009;&#x000b1;&#x02009;0.5</td><td align="char" valign="top" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Haemoglobin, g/dL</td><td align="center" valign="top" rowspan="1" colspan="1">13.7&#x02009;&#x000b1;&#x02009;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">13.5&#x02009;&#x000b1;&#x02009;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">13.7&#x02009;&#x000b1;&#x02009;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">13.8&#x02009;&#x000b1;&#x02009;1.9</td><td align="char" valign="top" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c, median (IQR), %</td><td align="char" valign="top" rowspan="1" colspan="1">6.1 (5.7, 6.8)</td><td align="char" valign="top" rowspan="1" colspan="1">5.7 (5.6, 5.9)</td><td align="char" valign="top" rowspan="1" colspan="1">5.8 (5.7, 6.1)</td><td align="char" valign="top" rowspan="1" colspan="1">6.6 (6.1, 7.5)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">eGFR</td><td align="center" valign="top" rowspan="1" colspan="1">74.7&#x02009;&#x000b1;&#x02009;33.5</td><td align="center" valign="top" rowspan="1" colspan="1">80.3&#x02009;&#x000b1;&#x02009;40.5</td><td align="center" valign="top" rowspan="1" colspan="1">75.9&#x02009;&#x000b1;&#x02009;33.7</td><td align="center" valign="top" rowspan="1" colspan="1">71.4&#x02009;&#x000b1;&#x02009;29.0</td><td align="char" valign="top" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD stage</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">G1</td><td align="char" valign="top" rowspan="1" colspan="1">115 (22%)</td><td align="char" valign="top" rowspan="1" colspan="1">39 (28%)</td><td align="char" valign="top" rowspan="1" colspan="1">26 (23%)</td><td align="char" valign="top" rowspan="1" colspan="1">50 (18%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">G2</td><td align="char" valign="top" rowspan="1" colspan="1">241 (45%)</td><td align="char" valign="top" rowspan="1" colspan="1">59 (42%)</td><td align="char" valign="top" rowspan="1" colspan="1">49 (43%)</td><td align="char" valign="top" rowspan="1" colspan="1">133 (48%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">G3a</td><td align="char" valign="top" rowspan="1" colspan="1">103 (19%)</td><td align="char" valign="top" rowspan="1" colspan="1">26 (18%)</td><td align="char" valign="top" rowspan="1" colspan="1">22 (20%)</td><td align="char" valign="top" rowspan="1" colspan="1">55 (20%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">G3b</td><td align="char" valign="top" rowspan="1" colspan="1">50 (9%)</td><td align="char" valign="top" rowspan="1" colspan="1">15 (11%)</td><td align="char" valign="top" rowspan="1" colspan="1">10 (9%)</td><td align="char" valign="top" rowspan="1" colspan="1">25 (9%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">G4</td><td align="char" valign="top" rowspan="1" colspan="1">25 (5%)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (2%)</td><td align="char" valign="top" rowspan="1" colspan="1">6 (5%)</td><td align="char" valign="top" rowspan="1" colspan="1">16 (6%)</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BNP, median (IQR)</td><td align="char" valign="top" rowspan="1" colspan="1">78.2 (38.1, 174.0)</td><td align="char" valign="top" rowspan="1" colspan="1">73.3 (36.8, 198.5)</td><td align="char" valign="top" rowspan="1" colspan="1">92.7 (52.6, 237.0)<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">70.9 (32.1, 159.0)</td><td align="char" valign="top" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UACR, median (IQR)</td><td align="char" valign="top" rowspan="1" colspan="1">20.9 (8.4, 65.6)</td><td align="char" valign="top" rowspan="1" colspan="1">12.6 (6.2, 42.9)</td><td align="char" valign="top" rowspan="1" colspan="1">14.9 (8.7, 46.1)<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">26.8 (10.9, 93.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Albuminuria, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">222 (42%)</td><td align="char" valign="top" rowspan="1" colspan="1">47 (33%)</td><td align="char" valign="top" rowspan="1" colspan="1">41 (36%)<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">134 (48%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">431 (81%)</td><td align="char" valign="top" rowspan="1" colspan="1">122 (86%)</td><td align="char" valign="top" rowspan="1" colspan="1">90 (80%)</td><td align="char" valign="top" rowspan="1" colspan="1">219 (78%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003b2;&#x02010;blocker, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">394 (74%)</td><td align="char" valign="top" rowspan="1" colspan="1">102 (72%)</td><td align="char" valign="top" rowspan="1" colspan="1">95 (84%)<xref ref-type="fn" rid="ehf212516-note-0003">*</xref>
<sup>,</sup>
<xref ref-type="fn" rid="ehf212516-note-0004">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">197 (70%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ca channel blocker, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">201 (38%)</td><td align="char" valign="top" rowspan="1" colspan="1">46 (32%)</td><td align="char" valign="top" rowspan="1" colspan="1">42 (37%)</td><td align="char" valign="top" rowspan="1" colspan="1">113 (40%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Loop diuretics, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">275 (51%)</td><td align="char" valign="top" rowspan="1" colspan="1">66 (47%)</td><td align="char" valign="top" rowspan="1" colspan="1">62 (55%)</td><td align="char" valign="top" rowspan="1" colspan="1">147 (53%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spironolactone, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">145 (27%)</td><td align="char" valign="top" rowspan="1" colspan="1">37 (26%)</td><td align="char" valign="top" rowspan="1" colspan="1">33 (29%)</td><td align="char" valign="top" rowspan="1" colspan="1">75 (27%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thiazide, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">22 (4%)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (3%)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (4%)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (5%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statin, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">262 (49%)</td><td align="char" valign="top" rowspan="1" colspan="1">53 (37%)</td><td align="char" valign="top" rowspan="1" colspan="1">52 (46%)</td><td align="char" valign="top" rowspan="1" colspan="1">157 (56%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oral diabetes medication, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">132 (25%)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="char" valign="top" rowspan="1" colspan="1">132 (47%)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulin use, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">28 (5%)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="char" valign="top" rowspan="1" colspan="1">28 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aspirin, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">289 (60%)</td><td align="char" valign="top" rowspan="1" colspan="1">76 (62%)</td><td align="char" valign="top" rowspan="1" colspan="1">62 (61%)</td><td align="char" valign="top" rowspan="1" colspan="1">151 (58%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Warfarin, <italic>n</italic> (%)</td><td align="char" valign="top" rowspan="1" colspan="1">162 (33%)</td><td align="char" valign="top" rowspan="1" colspan="1">39 (32%)</td><td align="char" valign="top" rowspan="1" colspan="1">33 (32%)</td><td align="char" valign="top" rowspan="1" colspan="1">90 (35%)</td><td align="char" valign="top" rowspan="1" colspan="1">0.84</td></tr></tbody></table><table-wrap-foot id="ehf212516-ntgp-0001"><fn id="ehf212516-note-0001"><p>Two patients are missing information on NYHA functional class. Left ventricular dimensions and mass were indexed to body surface area as per European Association of Cardiovascular Imaging (EACI) guidelines.<xref rid="ehf212516-bib-0034" ref-type="ref">34</xref> Left ventricular hypertrophy (LVH) was defined as LV mass index (LVMI) &#x0003e;115&#x02009;g/m<sup>2</sup> in men or&#x02009;&#x0003e;&#x02009;95&#x02009;g/m<sup>2</sup> in women. Left ventricular geometry was categorized as normal, concentric remodelling (RWT&#x02009;&#x0003e;&#x02009;0.42, normal LVMI), concentric hypertrophy (RWT&#x02009;&#x0003e;&#x02009;0.42, elevated LVMI), or eccentric hypertrophy (RWT&#x02009;&#x0003c;&#x02009;0.42, elevated LVMI). CKD stage was classified by the recommendation of Kidney Disease: Improving Global Outcomes (KDIGO).<xref rid="ehf212516-bib-0035" ref-type="ref">35</xref> Baseline characteristics stratified by NGR, IGT, and diabetes, and albuminuria are provided in Supporting Information, <italic>Table</italic>
<xref rid="ehf212516-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></fn><fn id="ehf212516-note-0002"><p>ACEI, angiotensin&#x02010;converting enzyme inhibitor; BP, blood pressure; BMI, body mass index; BNP, brain natriuretic peptide; DM, diabetes mellitus; HbA1c, haemoglobin A1c; HF, heart failure; LA, left atrium; LVEF, left ventricular ejection fraction; LV, left ventricular; LVH, left ventricular hypertrophy; eGFR, estimated glomerular filtration rate; UACR, urinary albumin&#x02010;to&#x02010;creatinine ratio.</p></fn><fn id="ehf212516-note-0003"><label>*</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 between the NGR and IGT subgroups.</p></fn><fn id="ehf212516-note-0004"><label>**</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 between the IGT and DM subgroups.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ehf212516-sec-0013"><label>3.2</label><title>Association between abnormality in glycaemic status, albuminuria and outcome</title><p>During the median follow&#x02010;up of 4.1&#x02009;years (IQR: 3.1&#x02013;5.0&#x02009;years), 151 patients experienced the composite outcome. <italic>Figure</italic>
<xref rid="ehf212516-fig-0002" ref-type="fig">2</xref> shows event rates (per 1000 person&#x02010;years) stratified by NGR, IGT, and DM. Patients with DM had numerically, but insignificantly, higher event rate [81.1 (65.5&#x02013;100.3) per 1000 person&#x02010;years] followed by IGT [74.3 (52.8&#x02013;104.5)] and NGR [71.1 (51.0&#x02013;97.3)]. When stratified by the presence of albuminuria, event rates were significantly higher in patients with albuminuria compared with those without albuminuria in all the three groups. HRs (95% CI) for the outcome in patients with albuminuria over those without it were 1.00 (0.61&#x02013;1.64; <italic>P</italic>&#x02009;=&#x02009;0.99) in IGT and 1.27 (0.84&#x02013;1.93; <italic>P</italic>&#x02009;=&#x02009;0.24) in DM at baseline after adjustment for potential confounders, including age, sex, ischaemic aetiology, NYHA functional class, systolic BP, heart rate, BMI, LVEF, history of HF hospitalization, and BNP (<italic>Table</italic>
<xref rid="ehf212516-tbl-0002" ref-type="table">2</xref>
<italic>A</italic>). Every 1% increase in HbA1c was associated with a 18% increase in the outcome (HR 1.18; 95% CI 1.05&#x02013;1.33, <italic>P</italic>&#x02009;=&#x02009;0.007) after adjustment for age, sex, ischaemic aetiology, NYHA functional class, systolic BP, heart rate, BMI, LVEF, history of HF hospitalization, BNP, and albuminuria (<italic>Table</italic>
<xref rid="ehf212516-tbl-0002" ref-type="table">2</xref>
<italic>A</italic>).</p><fig fig-type="Figure" xml:lang="en" id="ehf212516-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Event rates (per 1000 person&#x02010;years) for the composite of all&#x02010;cause death, non&#x02010;fatal myocardial infraction (MI), non&#x02010;fatal stroke, and hospitalization for worsening HF. Event rates were analysed with the exact probability test.</p></caption><graphic id="nlm-graphic-3" xlink:href="EHF2-6-1252-g002"/></fig><table-wrap id="ehf212516-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>(A) Prognostic significance of glycaemic status, haemoglobin A1c, and albuminuria in the overall samples. (B) Prognostic significance of glycaemic status with and without albuminuria in the overall samples</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">(A) Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Z</italic> score</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">NGR</td><td colspan="3" align="char" valign="top" rowspan="1">Reference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IGT</td><td align="char" valign="top" rowspan="1" colspan="1">1.00 (0.61&#x02013;1.64)</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DM</td><td align="char" valign="top" rowspan="1" colspan="1">1.27 (0.84&#x02013;1.93)</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td><td align="left" valign="top" rowspan="1" colspan="1">1.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c (per 1% increase)<xref ref-type="fn" rid="ehf212516-note-0007">a</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">1.18 (1.05&#x02013;1.33)</td><td align="left" valign="top" rowspan="1" colspan="1">0.007</td><td align="left" valign="top" rowspan="1" colspan="1">2.70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Albuminuria</td><td align="char" valign="top" rowspan="1" colspan="1">1.74 (1.22&#x02013;2.47)</td><td align="left" valign="top" rowspan="1" colspan="1">0.002</td><td align="left" valign="top" rowspan="1" colspan="1">3.09</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">(B) Variable (overall, <italic>n</italic>&#x02009;=&#x02009;535)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Z</italic> score</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">NGR without albuminuria</td><td colspan="3" align="char" valign="top" rowspan="1">Reference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NGR with albuminuria</td><td align="char" valign="top" rowspan="1" colspan="1">1.77 (0.91&#x02013;3.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IGT without albuminuria</td><td align="char" valign="top" rowspan="1" colspan="1">0.76 (0.36&#x02013;1.60)</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.72</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IGT with albuminuria</td><td align="char" valign="top" rowspan="1" colspan="1">2.25 (1.14&#x02013;4.42)</td><td align="left" valign="top" rowspan="1" colspan="1">0.019</td><td align="left" valign="top" rowspan="1" colspan="1">2.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DM without albuminuria</td><td align="char" valign="top" rowspan="1" colspan="1">1.45 (0.81&#x02013;2.60)</td><td align="left" valign="top" rowspan="1" colspan="1">0.213</td><td align="left" valign="top" rowspan="1" colspan="1">1.24</td></tr><tr style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">DM with albuminuria</td><td align="char" valign="top" rowspan="1" colspan="1">2.06 (1.17&#x02013;3.61)</td><td align="left" valign="top" rowspan="1" colspan="1">0.012</td><td align="left" valign="top" rowspan="1" colspan="1">2.51</td></tr></tbody></table><table-wrap-foot id="ehf212516-ntgp-0002"><fn id="ehf212516-note-0005"><p>DM, diabetes mellitus; HbA1c, haemoglobin A1c; HR, hazard ratio; IGT, impaired glucose tolerance; NGR, normal glucose regulation.</p></fn><fn id="ehf212516-note-0006"><p>DM, diabetes mellitus; HR, hazard ratio; IGT, impaired glucose tolerance; NGR, normal glucose regulation.</p></fn><fn id="ehf212516-note-0007"><label>a</label><p>Adjusted for age, sex, ischaemic aetiology, NYHA functional class, systolic blood pressure, heart rate, body mass index, LVEF, history of HF hospitalization, BNP, and albuminuria.</p></fn></table-wrap-foot></table-wrap><p>Albuminuria at baseline was significantly associated with the outcome (HR 1.74; 95% CI 1.22&#x02013;2.47; <italic>P</italic>&#x02009;=&#x02009;0.002) after adjustment for age, sex, ischaemic aetiology, NYHA functional class, systolic BP, heart rate, BMI, LVEF, history of HF hospitalization, and BNP (<italic>Table</italic>
<xref rid="ehf212516-tbl-0002" ref-type="table">2</xref>A). In addition, as compared with NGR without albuminuria, HRs of NGR, IGT, and DM with albuminuria were 1.77 (0.91&#x02013;3.45, <italic>P</italic>&#x02009;=&#x02009;0.09), 2.25 (1.14&#x02013;4.42, <italic>P</italic>&#x02009;=&#x02009;0.019), and 2.06 (1.17&#x02013;3.61, <italic>P</italic>&#x02009;=&#x02009;0.012), respectively, whereas there was no significant association between NGR, IGT, and DM without albuminuria (<italic>Table</italic>
<xref rid="ehf212516-tbl-0002" ref-type="table">2</xref>
<italic>B</italic>). We also noted significant interaction for the impact on the incidence of the composite endpoint between albuminuria and IGT (<italic>P</italic> for interaction&#x02009;=&#x02009;0.041) or DM (<italic>P</italic> for interaction&#x02009;=&#x02009;0.001) at baseline.</p><p>When stratifying by baseline LVEF (&#x02265;50%, preserved; &#x02265;40 to &#x0003c;50%, mid&#x02010;range; and&#x02009;&#x0003c;&#x02009;40%, reduced), in reduced LVEF but not in mid&#x02010;range and preserved LVEF subgroups, patients with diabetes and albuminuria and those with IGT and albuminuria tended to be associated with poor prognosis (Supporting Information, <italic>Table</italic>
<xref rid="ehf212516-supitem-0001" ref-type="supplementary-material">
<italic>S3</italic>
</xref>).</p><p>Of 328 patients, 14 (4.3%, 13 in IGT and one in NGR) and 22 patients (6.7%, all in NGR) were newly diagnosed as having DM [11.2 (6.6&#x02013;18.8)/1000 person&#x02010;years] and IGT [16.7 (95% CI 10.9&#x02013;25.7)/1000 person&#x02010;years], respectively, at 1&#x02010;year visit [median (IQR) 364 (339&#x02013;399) days from randomization] (<italic>Figure</italic>
<xref rid="ehf212516-fig-0001" ref-type="fig">1</xref>). At 1&#x02010;year follow&#x02010;up, 90 patients [25 (19.5%) in NGR, 19 (17.8%) in IGT, and 46 (18.0%) in DM] developed to albuminuria. In overall cohort, patients who developed albuminuria at 1&#x02009;year had similar incidence of the composite outcome compared with those with known albuminuria at baseline (Supporting Information, <italic>Figure S1A</italic>). When stratified by the presence of albuminuria at 1&#x02009;year, NGR, IGT, and DM were associated with poor prognosis in patients with NGR (2.97; 95% CI 1.02&#x02013;8.64; <italic>P</italic>&#x02009;=&#x02009;0.045) and IGT (3.59; 95% CI 1.04&#x02013;12.46; <italic>P</italic>&#x02009;=&#x02009;0.044), but not in DM (2.13; 95% CI 0.62&#x02013;7.34; <italic>P</italic>&#x02009;=&#x02009;0.230) (Supporting Information, <italic>Figure S1B</italic>&#x02013;<italic>D</italic>).</p></sec><sec id="ehf212516-sec-0014"><label>3.3</label><title>Determinant factors of impaired glucose tolerance or albuminuria in chronic heart failure</title><p>Determinants of IGT were identified as systolic BP (per 5&#x02009;mmHg increase, 1.09; 1.02&#x02013;1.17; <italic>P</italic>&#x02009;=&#x02009;0.016), age (per 5&#x02009;years increase, 1.16; 1.02&#x02013;1.32; <italic>P</italic>&#x02009;=&#x02009;0.025), and LVEF (per 5% decrease, 1.10; 1.01&#x02013;1.20; <italic>P</italic>&#x02009;=&#x02009;0.037) (Supporting Information, <italic>Table</italic>
<xref rid="ehf212516-supitem-0001" ref-type="supplementary-material">
<italic>S2</italic>
</xref>). <italic>Table</italic>
<xref rid="ehf212516-tbl-0003" ref-type="table">3</xref> shows the determinant factors of albuminuria by multivariable logistic models, including systolic BP, BNP, AF, and BMI. Of note, DM was also associated with albuminuria (odds ratio, 1.75; 95% CI 1.11&#x02013;2.75; <italic>P</italic>&#x02009;=&#x02009;0.016) but IGT was not (0.94; 0.54&#x02013;1.63; <italic>P</italic>&#x02009;=&#x02009;0.816). When we evaluated the association between abnormalities of glycaemic status and development of albuminuria, IGT and DM had numerically, but not statistically, higher odds ratios, while advanced NYHA class and history of HF hospitalization were associated with development of albuminuria (<italic>Table</italic>
<xref rid="ehf212516-tbl-0003" ref-type="table">3</xref>).</p><table-wrap id="ehf212516-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Relationships between abnormalities in glucose regulation and albuminuria at baseline and 1&#x02010;year follow&#x02010;up by multivariable logistic regression models</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variables</th><th align="center" valign="bottom" rowspan="1" colspan="1">Odds ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Z</italic> score</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">Albuminuria at baseline</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IGT</td><td align="char" valign="top" rowspan="1" colspan="1">0.94 (0.54&#x02013;1.63)</td><td align="char" valign="top" rowspan="1" colspan="1">0.816</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.23</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diabetes</td><td align="char" valign="top" rowspan="1" colspan="1">1.75 (1.11&#x02013;2.75)</td><td align="char" valign="top" rowspan="1" colspan="1">0.016</td><td align="char" valign="top" rowspan="1" colspan="1">2.41</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Systolic BP (per 5&#x02009;mmHg increase)</td><td align="char" valign="top" rowspan="1" colspan="1">1.12 (1.07&#x02013;1.19)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" valign="top" rowspan="1" colspan="1">4.27</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BNP (log)</td><td align="char" valign="top" rowspan="1" colspan="1">1.40 (1.18&#x02013;1.66)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" valign="top" rowspan="1" colspan="1">3.82</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Atrial fibrillation</td><td align="char" valign="top" rowspan="1" colspan="1">1.66 (1.13&#x02013;2.44)</td><td align="char" valign="top" rowspan="1" colspan="1">0.010</td><td align="char" valign="top" rowspan="1" colspan="1">2.41</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="char" valign="top" rowspan="1" colspan="1">1.06 (1.01&#x02013;1.11)</td><td align="char" valign="top" rowspan="1" colspan="1">0.017</td><td align="char" valign="top" rowspan="1" colspan="1">2.38</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Albuminuria at 1&#x02009;year</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IGT</td><td align="char" valign="top" rowspan="1" colspan="1">0.96 (0.47&#x02013;1.96)</td><td align="char" valign="top" rowspan="1" colspan="1">0.916</td><td align="char" valign="top" rowspan="1" colspan="1">2.38</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diabetes</td><td align="char" valign="top" rowspan="1" colspan="1">1.33 (0.74&#x02013;2.40)</td><td align="char" valign="top" rowspan="1" colspan="1">0.338</td><td align="char" valign="top" rowspan="1" colspan="1">2.57</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">History of HF hospitalization</td><td align="char" valign="top" rowspan="1" colspan="1">1.94 (1.17&#x02013;3.22)</td><td align="char" valign="top" rowspan="1" colspan="1">0.010</td><td align="char" valign="top" rowspan="1" colspan="1">2.57</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NYHA class</td><td align="char" valign="top" rowspan="1" colspan="1">3.28 (1.23&#x02013;8.75)</td><td align="char" valign="top" rowspan="1" colspan="1">0.017</td><td align="char" valign="top" rowspan="1" colspan="1">2.38</td></tr></tbody></table><table-wrap-foot id="ehf212516-ntgp-0003"><fn id="ehf212516-note-0008"><p>We used backward and forward selection methods. The final model was determined as the one using backward selection by the lowest value of Akaike information criterion (AIC).</p></fn><fn id="ehf212516-note-0009"><p>BP, blood pressure; BMI, body mass index; BNP, brain natriuretic peptide; HF, hear failure; LVEF, left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="ehf212516-sec-0015"><label>4</label><title>Discussion</title><p>The novel findings of the present study are as follows: (i) although IGT itself was not associated with poor prognosis, it was a significant prognostic factor in CHF patients when complicated with albuminuria. (ii) Newly developed albuminuria was associated with poor prognosis in CHF patients with NGR or IGT. To the best of our knowledge, this is the first study that demonstrates the clinical significance of combined early stages of IGT and renal dysfunction in CHF patients. The present study also indicates the clinical importance of combined tests of OGTT and urinalysis to more accurately assess long&#x02010;term prognosis of CHF patients.</p><sec id="ehf212516-sec-0016"><label>4.1</label><title>Prevalence and incidence of impaired glucose tolerance and diabetes mellitus in chronic heart failure patients</title><p>By repeating OGTT and urinalysis, we confirmed higher prevalence of IGT in CHF patients.<xref rid="ehf212516-bib-0001" ref-type="ref">1</xref>, <xref rid="ehf212516-bib-0002" ref-type="ref">2</xref>, <xref rid="ehf212516-bib-0003" ref-type="ref">3</xref>, <xref rid="ehf212516-bib-0004" ref-type="ref">4</xref>, <xref rid="ehf212516-bib-0005" ref-type="ref">5</xref> Indeed, 23% of our CHF patients had IGT, a higher prevalence than in Japanese general population (14.6%).<xref rid="ehf212516-bib-0003" ref-type="ref">3</xref> A previous study with OGTT showed that in outpatients with HF and LVEF&#x02009;&#x02264;&#x02009;45%, the prevalence of IGT was 23%,<xref rid="ehf212516-bib-0005" ref-type="ref">5</xref> a consistent finding with our present finding. In the present study, IGT was related with age, systolic BP, and LVEF in the logistic regression analysis. These results suggest that insulin resistance is associated with severity of HF, a consistent finding with the previous study that insulin resistance was associated with exercise intolerance partly through reduced coronary flow reserve.<xref rid="ehf212516-bib-0023" ref-type="ref">23</xref> In the present study, we have extended the clinical relevance of IGT and DM by repeated evaluation of glucose regulation; in CHF, the incidence rate of newly diagnosed IGT and DM was 16.7 (95% CI 10.9&#x02013;25.7)/1000 person&#x02010;years and 11.2 (6.6&#x02013;18.8)/1000 person&#x02010;years, respectively. This incident rate of newly diagnosed DM was higher than in Japanese general population (age 19&#x02013;82&#x02009;years) with 8.8/1000 person&#x02010;years,<xref rid="ehf212516-bib-0024" ref-type="ref">24</xref> although no report is yet available for the incidence of IGT. Thus, it is important to continuously monitor glucose tolerance in CHF patients.</p></sec><sec id="ehf212516-sec-0017"><label>4.2</label><title>Prognostic implications of impaired glucose tolerance and diabetes mellitus in chronic heart failure</title><p>In terms of the prognostic importance of IGT and DM in CHF patients, our findings extend on the previous studies assessing the prognostic significance of combined glucose intolerance and albuminuria. In the previous studies, IGT was assessed in relation to baseline serum glucose,<xref rid="ehf212516-bib-0004" ref-type="ref">4</xref>, <xref rid="ehf212516-bib-0007" ref-type="ref">7</xref> insulin,<xref rid="ehf212516-bib-0006" ref-type="ref">6</xref> and HbA1c<xref rid="ehf212516-bib-0025" ref-type="ref">25</xref> levels. In the present study, we employed OGTT as a gold standard to evaluate IGT and DM. A recent study with OGTT at baseline showed an association of known or newly diagnosed DM and prognosis in CHF patients.<xref rid="ehf212516-bib-0005" ref-type="ref">5</xref> In this study with 413 CHF patients, the mortality rate was almost two&#x02010;fold higher in DM patients than in those without it,<xref rid="ehf212516-bib-0005" ref-type="ref">5</xref> although prognostic impact of IGT was not examined. In the present study, for the first time, we evaluated the prognostic significance of IGT in CHF patients by OGTT. In the present study, IGT was associated with systolic BP and LVEF, whereas no association was noted between IGT and long&#x02010;term prognosis, suggesting that IGT is related to the severity of HF, but a longer period would be needed for future adverse effects.</p><p>In terms of the prognostic impact of DM in CHF, the adjusted HR of DM was numerically higher but statistically insignificant. In contrast, elevated HbA1c was significantly associated with higher event rate, as in the previous report.<xref rid="ehf212516-bib-0025" ref-type="ref">25</xref> In the present study, HbA1c levels were lower (mean 6.6%) compared with the previous study (7.7%),<xref rid="ehf212516-bib-0008" ref-type="ref">8</xref> suggesting that DM was well controlled and thus adverse prognostic impacts of DM were not so evident.</p></sec><sec id="ehf212516-sec-0018"><label>4.3</label><title>Prognostic significance of albuminuria in chronic heart failure with references to normal glucose regulation, impaired glucose tolerance, and diabetes mellitus</title><p>In the present study, we first demonstrated the prognostic significance of the combined early stages of glycaemic abnormality (IGT) and renal dysfunction (albuminuria) in CHF patients by repeating OGTT and urinalysis. In fact, patients with NGR and albuminuria had higher event rate than in those with IGT or DM without albuminuria, suggesting that albuminuria has more prognostic impact than glycaemic abnormalities in CHF patients.</p><p>We and others have previously shown the prognostic impacts of DM and albuminuria in CHF patients<xref rid="ehf212516-bib-0012" ref-type="ref">12</xref>, <xref rid="ehf212516-bib-0026" ref-type="ref">26</xref>, <xref rid="ehf212516-bib-0027" ref-type="ref">27</xref>, <xref rid="ehf212516-bib-0028" ref-type="ref">28</xref>, <xref rid="ehf212516-bib-0029" ref-type="ref">29</xref> (<italic>Table</italic>
<xref rid="ehf212516-tbl-0004" ref-type="table">4</xref>). A previous study showed that albuminuria was associated with poor prognosis in CHF patients.<xref rid="ehf212516-bib-0028" ref-type="ref">28</xref> The present findings have extended this observation by demonstrating the prognostic interaction between glycaemic abnormalities and albuminuria in CHF patients. In the present study, newly developed albuminuria had similar prognostic significance to known albuminuria in patients with NGR and IGT, suggesting usefulness of repeating urinalysis to assess the prognostic risk of renal dysfunction in this population. Furthermore, after adjusting confounders, we noted a 125% increase in the prognostic risk of albuminuria in HF patients with IGT. A recent study by echocardiography has shown that in patients with Type I DM, myocardial deformation was associated primarily with the presence of microalbuminuria.<xref rid="ehf212516-bib-0017" ref-type="ref">17</xref> We also previously demonstrated that combined abnormalities of glycaemic regulation and albuminuria impair cardiac function, especially diastolic function, and influence the prognosis in CHF patients.<xref rid="ehf212516-bib-0013" ref-type="ref">13</xref> Indeed, in the present study, NGR and IGT patients with newly developed albuminuria had similar prognosis compared with those with known albuminuria, and severity of CHF was associated with progression of albuminuria, suggesting that reduction in albuminuria may be beneficial for CHF patients with NGR and IGT. However, it is still controversial whether albuminuria is a therapeutic target. This question may be answered by the ongoing clinical trials in HF patients with any glycaemic status to evaluate the effects of sodium&#x02010;glucose co&#x02010;transporter 2 inhibitors (empagliflozin/dapagliflozin), which are known to reduce UACR and renal events in Type II DM.<xref rid="ehf212516-bib-0030" ref-type="ref">30</xref>, <xref rid="ehf212516-bib-0031" ref-type="ref">31</xref>
</p><table-wrap id="ehf212516-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of patients, measurements, and outcomes with previous heart failure studies</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of patients</th><th align="center" valign="bottom" rowspan="1" colspan="1">Study patients</th><th align="center" valign="bottom" rowspan="1" colspan="1">Measurements</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody valign="top"><tr><td colspan="5" style="border-bottom:solid 1px #000000" align="left" valign="top" rowspan="1">Prevalence of IGT or diabetes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Suskin <italic>et al</italic>.<xref rid="ehf212516-bib-0001" ref-type="ref">1</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">663</td><td align="left" valign="top" rowspan="1" colspan="1">NYHA II&#x02013;IV, EF&#x02009;&#x0003c;&#x02009;40%</td><td align="left" valign="top" rowspan="1" colspan="1">Fasting plasma glucose and insulin levels</td><td align="left" valign="top" rowspan="1" colspan="1">27%, diabetes; 8%, newly diagnosed diabetes; 9%, elevated glucose levels</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Witteles <italic>et al</italic>.<xref rid="ehf212516-bib-0002" ref-type="ref">2</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">Idiopathic dilated cardiomyopathy</td><td align="left" valign="top" rowspan="1" colspan="1">OGTT</td><td align="left" valign="top" rowspan="1" colspan="1">49%, IGT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kim <italic>et al</italic>.<xref rid="ehf212516-bib-0003" ref-type="ref">3</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">56</td><td align="left" valign="top" rowspan="1" colspan="1">Dilated cardiomyopathy</td><td align="left" valign="top" rowspan="1" colspan="1">OGTT</td><td align="left" valign="top" rowspan="1" colspan="1">50%, IGT; 26.8%, newly diagnosed diabetes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Berry <italic>et al</italic>.<xref rid="ehf212516-bib-0004" ref-type="ref">4</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">454</td><td align="left" valign="top" rowspan="1" colspan="1">Acute HF</td><td align="left" valign="top" rowspan="1" colspan="1">Plasma glucose level</td><td align="left" valign="top" rowspan="1" colspan="1">13%, IGT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Egstrup <italic>et al</italic>.<xref rid="ehf212516-bib-0005" ref-type="ref">5</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">413</td><td align="left" valign="top" rowspan="1" colspan="1">Outpatients with HF and LVEF&#x02009;&#x02264;&#x02009;45%</td><td align="left" valign="top" rowspan="1" colspan="1">OGTT</td><td align="left" valign="top" rowspan="1" colspan="1">23%, IGT; 18%, newly diagnosed diabetes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Present study</td><td align="char" valign="top" rowspan="1" colspan="1">535</td><td align="left" valign="top" rowspan="1" colspan="1">Chronic HF with a history of hypertension (82%; LVEF&#x02009;&#x0003e;&#x02009;40%)</td><td align="left" valign="top" rowspan="1" colspan="1">OGTT</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x0003c;At enrolment&#x0003e;23%, IGT; 0.5%, newly diagnosed diabetes</p>
<p>&#x0003c;At 1&#x02009;year&#x0003e;5%, newly diagnosed IGT; 2.5%, newly diagnosed diabetes</p>
</td></tr><tr><td colspan="5" style="border-bottom:solid 1px #000000" align="left" valign="top" rowspan="1">Prognostic significance of abnormalities in glucose regulation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Doehner <italic>et al</italic>.<xref rid="ehf212516-bib-0006" ref-type="ref">6</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">105 (male)</td><td align="left" valign="top" rowspan="1" colspan="1">Chronic HF</td><td align="left" valign="top" rowspan="1" colspan="1">ivGTT</td><td align="left" valign="top" rowspan="1" colspan="1">HR 0.28 (0.14&#x02013;0.55, <italic>P</italic>&#x02009;=&#x02009;0.0003) of insulin sensitivity<xref ref-type="fn" rid="ehf212516-note-0011">a</xref> for all&#x02010;cause death</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gerstein <italic>et al</italic>.<xref rid="ehf212516-bib-0025" ref-type="ref">25</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">2412</td><td align="left" valign="top" rowspan="1" colspan="1">Chronic HF</td><td align="left" valign="top" rowspan="1" colspan="1">HbA1c</td><td align="left" valign="top" rowspan="1" colspan="1">HR 1.22 (1.16&#x02013;1.29, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) per 1% HbA1c increase for all&#x02010;cause death</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Berry <italic>et al</italic>.<xref rid="ehf212516-bib-0004" ref-type="ref">4</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">454</td><td align="left" valign="top" rowspan="1" colspan="1">Acute HF</td><td align="left" valign="top" rowspan="1" colspan="1">Plasma glucose level</td><td align="left" valign="top" rowspan="1" colspan="1">HR 1.41 (0.92&#x02013;2.16, <italic>P</italic>&#x02009;=&#x02009;0.12) of IGT for all&#x02010;cause death</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kosiborod <italic>et al</italic>.<xref rid="ehf212516-bib-0007" ref-type="ref">7</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">50&#x02009;532</td><td align="left" valign="top" rowspan="1" colspan="1">Post discharge after acute HF, Age&#x02009;&#x0003e;&#x02009;65&#x02009;years (retrospective)</td><td align="left" valign="top" rowspan="1" colspan="1">Plasma glucose level</td><td align="left" valign="top" rowspan="1" colspan="1">HR 1.00 (0.99&#x02013;1.01, <italic>P</italic>&#x02009;=&#x02009;0.75) for all&#x02010;cause mortality (per 10&#x02009;mg/dL admission serum glucose increase)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Present study</td><td align="char" valign="top" rowspan="1" colspan="1">535</td><td align="left" valign="top" rowspan="1" colspan="1">Chronic HF with a history of hypertension (82%; LVEF&#x02009;&#x0003e;&#x02009;40%)</td><td align="left" valign="top" rowspan="1" colspan="1">OGTT</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>HR 1.18 (1.05&#x02013;1.33, <italic>P</italic>&#x02009;=&#x02009;0.007) per 1% HbA1c increase for composite outcome</p>
<p>HR 1.00 (0.61&#x02013;1.64, <italic>P</italic>&#x02009;=&#x02009;0.99) for IGT</p>
<p>HR 2.25 (1.14&#x02013;4.42, <italic>P</italic>&#x02009;=&#x02009;0.019) for IGT complicated with albuminuria</p>
</td></tr></tbody></table><table-wrap-foot id="ehf212516-ntgp-0004"><fn id="ehf212516-note-0010"><p>EF, ejection fraction; HbA1c, haemoglobin A1c; HF, heart failure; HR, hazard ratio; IGT, impaired glucose tolerance; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OGTT, oral glucose tolerance test.</p></fn><fn id="ehf212516-note-0011"><label>a</label><p>Insulin sensitivity&#x02014;the inverse of insulin resistance&#x02014;is defined as the fraction of the glucose distribution space cleared per minute by insulin&#x02010;dependent glucose disposal relative to the concentration of insulin and is expressed in min/&#x003bc;U/mL.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ehf212516-sec-0019"><label>4.4</label><title>Study limitations</title><p>Several limitations should be mentioned for the present study. First, as our patient population is relatively homogeneous with Japanese patients, external validation studies should be conducted. Second, in the present study, we enrolled CHF patients with hypertension based on the study design, majority of them had preserved EF, which limits the data on clinical significance of IGT and albuminuria in patients with reduced EF. Third, timing of follow&#x02010;up OGTT (approximately 1&#x02009;year) may be relatively short to fully evaluate the impact of IGT or DM. Finally, because we excluded 19 patients with IGF, we were unable to evaluate the association between IGF and prognosis. However, IGF has been shown to be less significantly associated with cardiovascular events and mortality.<xref rid="ehf212516-bib-0032" ref-type="ref">32</xref>, <xref rid="ehf212516-bib-0033" ref-type="ref">33</xref>
</p></sec></sec><sec id="ehf212516-sec-0020"><label>5</label><title>Conclusions</title><p>In the present study, we were able to demonstrate that IGT is associated with poor prognosis when complicated by albuminuria in CHF patients, demonstrating the importance of combined early stages of glucose intolerance and renal dysfunction in the management of HF.</p></sec><sec sec-type="COI-statement" id="ehf212516-sec-0023"><title>Conflict of interest</title><p>The Department of Evidence&#x02010;based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, is supported in part by the unrestricted research grants from Daiichi Sankyo Co., Ltd. (Tokyo, Japan), Bayer Yakuhin, Ltd. (Osaka, Japan), Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan), Kowa Pharmaceutical Co., Ltd. (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Dainippon Sumitomo Pharma, Co., Ltd. (Osaka, Japan), and Nippon Boehringer Ingelheim Co., Ltd. (Tokyo, Japan). H.S. has received lecture fees from Bayer Yakuhin, Ltd. (Osaka, Japan), Daiichi Sankyo Co., Ltd. (Tokyo, Japan), and Novartis Pharma K.K. (Tokyo, Japan).</p></sec><sec id="ehf212516-sec-0022"><title>Funding</title><p>The SUPPORT trial was carried out, supported by grants&#x02010;in&#x02010;aid from the Ministry of Health, Labour and Welfare and from the Ministry of Education, Culture, Sports, Science and Technology, Japan (KAKENHI&#x02010;PROJECT&#x02010;17K15821).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="ehf212516-supitem-0001"><caption><p>
<bold>Table S1.</bold> Baseline characteristics stratified by glycemic control condition and albuminuria.</p><p>
<bold>Table S2.</bold> Determinants of IGT in HF patients by multivariable logistic regression model.</p><p>
<bold>Table S3.</bold> Prognostic significance of glycemic status and albuminuria after adjusting for age, sex, and BNP levels stratified by preserved, mid&#x02010;range, and reduced LVEF subgroups.</p><p>
<bold>Figure S1.</bold> Kaplan&#x02013;Meier survival curves in (A) CHF patients in overall, (B) those with NGR, (C) those with IGT, and (D) those with DM stratified by the status of albuminuria at 1&#x02010;year visit; without albuminuria or developed albuminuria at 1&#x02009;year, and known albuminuria., setting date at 1&#x02010;year visit as observation time 0. HRs are adjusted for age, sex and BNP at 1&#x02009;year. Abbreviations; w/o, without.</p></caption><media xlink:href="EHF2-6-1252-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ehf212516-sec-0021"><title>Acknowledgements</title><p>The authors wish to thank the patients and staff of the SUPPORT trial for their important contributions.</p></ack><ref-list id="ehf212516-bibl-0001" content-type="cited-references"><title>References</title><ref id="ehf212516-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ehf212516-cit-0002">
<string-name>
<surname>Suskin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>McKelvie</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Burns</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Latini</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pericak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Probstfield</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rouleau</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Sigouin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Solymoss</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Tsuyuki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>. <article-title>Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure</article-title>. <source xml:lang="en">Eur Heart J</source>
<year>2000</year>; <volume>21</volume>: <fpage>1368</fpage>&#x02013;<lpage>1375</lpage>.<pub-id pub-id-type="pmid">10952826</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ehf212516-cit-0003">
<string-name>
<surname>Witteles</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Jamali</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Reaven</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Fowler</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>
<year>2004</year>; <volume>44</volume>: <fpage>78</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">15234411</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ehf212516-cit-0004">
<string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nakatani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hashimura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Komamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kanzaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Asakura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Asanuma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kokubo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tomoike</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kitakaze</surname>
<given-names>M</given-names>
</string-name>. <article-title>Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy</article-title>. <source xml:lang="en">Hypertens Res</source>
<year>2006</year>; <volume>29</volume>: <fpage>775</fpage>&#x02013;<lpage>782</lpage>.<pub-id pub-id-type="pmid">17283864</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ehf212516-cit-0005">
<string-name>
<surname>Berry</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Brett</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Norrie</surname>
<given-names>J</given-names>
</string-name>. <article-title>Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure</article-title>. <source xml:lang="en">Heart</source>
<year>2008</year>; <volume>94</volume>: <fpage>296</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">17664189</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ehf212516-cit-0006">
<string-name>
<surname>Egstrup</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gustafsson</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kistorp</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Hildebrandt</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Tuxen</surname>
<given-names>CD</given-names>
</string-name>. <article-title>Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis</article-title>. <source xml:lang="en">Eur J Heart Fail</source>
<year>2011</year>; <volume>13</volume>: <fpage>319</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">21148170</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ehf212516-cit-0007">
<string-name>
<surname>Doehner</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Rauchhaus</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ponikowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Godsland</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>von Haehling</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Okonko</surname>
<given-names>DO</given-names>
</string-name>, <string-name>
<surname>Leyva</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Proudler</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Coats</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>
<year>2005</year>; <volume>46</volume>: <fpage>1019</fpage>&#x02013;<lpage>1026</lpage>.<pub-id pub-id-type="pmid">16168285</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ehf212516-cit-0008">
<string-name>
<surname>Kosiborod</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Spertus</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Masoudi</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Havranek</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Krumholz</surname>
<given-names>HM</given-names>
</string-name>. <article-title>Elevated admission glucose and mortality in elderly patients hospitalized with heart failure</article-title>. <source xml:lang="en">Circulation</source>
<year>2009</year>; <volume>119</volume>: <fpage>1899</fpage>&#x02013;<lpage>1907</lpage>.<pub-id pub-id-type="pmid">19332465</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ehf212516-cit-0009">
<collab collab-type="authors">Authors/Task Force M</collab>
, <string-name>
<surname>Ryden</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Berne</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cosentino</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Danchin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Deaton</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Escaned</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hammes</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Huikuri</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Marre</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Marx</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mellbin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ostergren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Patrono</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Seferovic</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Uva</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Taskinen</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Tendera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tuomilehto</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Valensi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zamorano</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>ESCCfP</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zamorano</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Achenbach</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baumgartner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Bueno</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dean</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Deaton</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Erol</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fagard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hasdai</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hoes</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Kirchhof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Knuuti</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kolh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lancellotti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Linhart</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nihoyannopoulos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Piepoli</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Ponikowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sirnes</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Tamargo</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Tendera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Torbicki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wijns</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Windecker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Document</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>De Backer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sirnes</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Ezquerra</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Avogaro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Badimon</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Baranova</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Baumgartner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Betteridge</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ceriello</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fagard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Funck&#x02010;Brentano</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gulba</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Hasdai</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hoes</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Kjekshus</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Knuuti</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kolh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lev</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mueller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Neyses</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nilsson</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Perk</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ponikowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Reiner</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Sattar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Schachinger</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Scheen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schirmer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Stromberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sudzhaeva</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tamargo</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Viigimaa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vlachopoulos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Xuereb</surname>
<given-names>RG</given-names>
</string-name>. <article-title>ESC Guidelines on diabetes, pre&#x02010;diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre&#x02010;diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)</article-title>. <source xml:lang="en">Eur Heart J</source>
<year>2013</year>; <volume>34</volume>: <fpage>3035</fpage>&#x02013;<lpage>3087</lpage>.<pub-id pub-id-type="pmid">23996285</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ehf212516-cit-0010">
<string-name>
<surname>Orchard</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>YF</given-names>
</string-name>, <string-name>
<surname>Ferrell</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Petro</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ellis</surname>
<given-names>DE</given-names>
</string-name>. <article-title>Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh epidemiology of diabetes complication study</article-title>. <source xml:lang="en">Kidney Int</source>
<year>2002</year>; <volume>62</volume>: <fpage>963</fpage>&#x02013;<lpage>970</lpage>.<pub-id pub-id-type="pmid">12164879</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ehf212516-cit-0011">
<string-name>
<surname>Parvanova</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Trevisan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Iliev</surname>
<given-names>IP</given-names>
</string-name>, <string-name>
<surname>Dimitrov</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Vedovato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tiengo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Remuzzi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ruggenenti</surname>
<given-names>P</given-names>
</string-name>. <article-title>Insulin resistance and microalbuminuria: a cross&#x02010;sectional, case&#x02010;control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion</article-title>. <source xml:lang="en">Diabetes</source>
<year>2006</year>; <volume>55</volume>: <fpage>1456</fpage>&#x02013;<lpage>1462</lpage>.<pub-id pub-id-type="pmid">16644705</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ehf212516-cit-0012">
<string-name>
<surname>Mykkanen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zaccaro</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Wagenknecht</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Robbins</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Gabriel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Haffner</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study</article-title>. <source xml:lang="en">Diabetes</source>
<year>1998</year>; <volume>47</volume>: <fpage>793</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">9588452</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ehf212516-cit-0013">
<string-name>
<surname>Miura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sakata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nochioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tadaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ushigome</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yamauchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Investigators C. Prognostic impact of subclinical microalbuminuria in patients with chronic heart failure</article-title>. <source xml:lang="en">Circ J</source>
<year>2014</year>; <volume>78</volume>: <fpage>2890</fpage>&#x02013;<lpage>2898</lpage>.<pub-id pub-id-type="pmid">25421233</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ehf212516-cit-0014">
<string-name>
<surname>Jensen</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Sogaard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Bech</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fritz Hansen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Biering&#x02010;Sorensen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Jorgensen</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Galatius</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Madsen</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Rossing</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>JS</given-names>
</string-name>. <article-title>Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand &#x00026; 1 study</article-title>. <source xml:lang="en">JACC Cardiovasc Imaging</source>
<year>2015</year>; <volume>8</volume>: <fpage>400</fpage>&#x02013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">25746329</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ehf212516-cit-0015">
<string-name>
<surname>Sakata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shiba</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nochioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saga</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shinozaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sugi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sekiguchi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Komaru</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fukuchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nozaki</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hiramoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tamaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ibayashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ishide</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Maruyama</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tsuji</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Investigators</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Investigators</surname>
<given-names>ST</given-names>
</string-name>. <article-title>Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial</article-title>. <source xml:lang="en">Eur Heart J</source>
<year>2015</year>; <volume>36</volume>: <fpage>915</fpage>&#x02013;<lpage>923</lpage>.<pub-id pub-id-type="pmid">25637937</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ehf212516-cit-0016">
<string-name>
<surname>Sakata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nochioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tadaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shiba</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial&#x02014;rationale and design</article-title>. <source xml:lang="en">J Cardiol</source>
<year>2013</year>; <volume>62</volume>: <fpage>31</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">23769179</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ehf212516-cit-0017">
<string-name>
<surname>Genuth</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alberti</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Defronzo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kahn</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kitzmiller</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Knowler</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Lebovitz</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lernmark</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nathan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rizza</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Saudek</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Steffes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tuomilehto</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zimmet</surname>
<given-names>P</given-names>
</string-name>. <article-title>Expert Committee on the D, Classification of Diabetes M. Follow&#x02010;up report on the diagnosis of diabetes mellitus</article-title>. <source xml:lang="en">Diabetes Care</source>
<year>2003</year>; <volume>26</volume>: <fpage>3160</fpage>&#x02013;<lpage>3167</lpage>.<pub-id pub-id-type="pmid">14578255</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ehf212516-cit-0018">
<string-name>
<surname>Stevens</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>A</given-names>
</string-name>. <article-title>Kidney disease: improving global outcomes chronic kidney disease guideline development work group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline</article-title>. <source xml:lang="en">Ann Intern Med</source>
<year>2013</year>; <volume>158</volume>: <fpage>825</fpage>&#x02013;<lpage>830</lpage>.<pub-id pub-id-type="pmid">23732715</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ehf212516-cit-0019">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Battler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Ellis</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Every</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Flaherty</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Krumholz</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Simoons</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Van De Werf</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Weintraub</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Morrisson</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>HV</given-names>
</string-name>, <string-name>
<surname>Cannom</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Chitwood</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Cigarroa</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Collins&#x02010;Nakai</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Ellis</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Gibbons</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Grover</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Heidenreich</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Khandheria</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Knoebel</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Krumholz</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Malenka</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Mark</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>McKay</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Passamani</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Radford</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Riner</surname>
<given-names>RN</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Shemin</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Van Fossen</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Verrier</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Watkins</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Phoubandith</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Furnelli</surname>
<given-names>T</given-names>
</string-name>. <article-title>American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>
<year>2001</year>; <volume>38</volume>: <fpage>2114</fpage>&#x02013;<lpage>2130</lpage>.<pub-id pub-id-type="pmid">11738323</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ehf212516-cit-0020">
<string-name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Olofsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ostergren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pocock</surname>
<given-names>S</given-names>
</string-name>, 
<collab collab-type="authors">Investigators C, Committees</collab>
. <article-title>Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM&#x02010;Overall programme</article-title>. <source xml:lang="en">Lancet</source>
<year>2003</year>; <volume>362</volume>: <fpage>759</fpage>&#x02013;<lpage>766</lpage>.<pub-id pub-id-type="pmid">13678868</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ehf212516-cit-0021">
<string-name>
<surname>Rahimi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Conrad</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Basu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dwight</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Woodward</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>MacMahon</surname>
<given-names>S</given-names>
</string-name>. <article-title>Risk prediction in patients with heart failure: a systematic review and analysis</article-title>. <source xml:lang="en">JACC Heart Fail</source>
<year>2014</year>; <volume>2</volume>: <fpage>440</fpage>&#x02013;<lpage>446</lpage>.<pub-id pub-id-type="pmid">25194291</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ehf212516-cit-0022">
<string-name>
<surname>Tsuji</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sakata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nochioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamauchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Onose</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Oikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kasahara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shiroto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Investigators</surname>
<given-names>C</given-names>
</string-name>. <article-title>Characterization of heart failure patients with mid&#x02010;range left ventricular ejection fraction&#x02014;a report from the CHART&#x02010;2 study</article-title>. <source xml:lang="en">Eur J Heart Fail</source>
<year>2017</year>; <volume>19</volume>: <fpage>1258</fpage>&#x02013;<lpage>1269</lpage>.<pub-id pub-id-type="pmid">28370829</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ehf212516-cit-0023">
<string-name>
<surname>Dafni</surname>
<given-names>U</given-names>
</string-name>. <article-title>Landmark analysis at the 25&#x02010;year landmark point</article-title>. <source xml:lang="en">Circ Cardiovasc Qual Outcomes</source>
<year>2011</year>; <volume>4</volume>: <fpage>363</fpage>&#x02013;<lpage>371</lpage>.<pub-id pub-id-type="pmid">21586725</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ehf212516-cit-0024">
<string-name>
<surname>Snoer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Monk&#x02010;Hansen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Simonsen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rasmusen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dela</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Prescott</surname>
<given-names>E</given-names>
</string-name>. <article-title>Insulin resistance and exercise tolerance in heart failure patients: linkage to coronary flow reserve and peripheral vascular function</article-title>. <source xml:lang="en">Cardiovasc Diabetol</source>
<year>2012</year>; <volume>11</volume>: <fpage>97</fpage>.<pub-id pub-id-type="pmid">22889317</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ehf212516-cit-0025">
<string-name>
<surname>Goto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Noda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsugane</surname>
<given-names>S</given-names>
</string-name>. <article-title>Incidence of type 2 diabetes in Japan: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">PLoS ONE</source>
<year>2013</year>; <volume>8</volume>: <elocation-id>e74699</elocation-id>.<pub-id pub-id-type="pmid">24040326</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ehf212516-cit-0026">
<string-name>
<surname>Gerstein</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Carlsson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Olofsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Investigators</surname>
<given-names>CP</given-names>
</string-name>. <article-title>The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program</article-title>. <source xml:lang="en">Arch Intern Med</source>
<year>2008</year>; <volume>168</volume>: <fpage>1699</fpage>&#x02013;<lpage>1704</lpage>.<pub-id pub-id-type="pmid">18695086</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ehf212516-cit-0027">
<string-name>
<surname>Miura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sakata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Miyata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nochioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tadaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ushigome</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yamauchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Onose</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tsuji</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Investigators</surname>
<given-names>C</given-names>
</string-name>. <article-title>Prognostic impact of diabetes mellitus in chronic heart failure according to presence of ischemic heart disease&#x02014;with special reference to nephropathy</article-title>. <source xml:lang="en">Circ J</source>
<year>2015</year>; <volume>79</volume>: <fpage>1764</fpage>&#x02013;<lpage>1772</lpage>.<pub-id pub-id-type="pmid">26004750</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ehf212516-cit-0028">
<string-name>
<surname>Dries</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Sweitzer</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Drazner</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>LW</given-names>
</string-name>, <string-name>
<surname>Gersh</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>
<year>2001</year>; <volume>38</volume>: <fpage>421</fpage>&#x02013;<lpage>428</lpage>.<pub-id pub-id-type="pmid">11499733</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ehf212516-cit-0029">
<string-name>
<surname>Jackson</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Gerstein</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Zetterstrand</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Olofsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, 
<collab collab-type="authors">Investigators C, Committees</collab>
. <article-title>Albuminuria in chronic heart failure: prevalence and prognostic importance</article-title>. <source xml:lang="en">Lancet</source>
<year>2009</year>; <volume>374</volume>: <fpage>543</fpage>&#x02013;<lpage>550</lpage>.<pub-id pub-id-type="pmid">19683640</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ehf212516-cit-0030">
<string-name>
<surname>Miura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shiba</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nochioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kohno</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Investigators</surname>
<given-names>C</given-names>
</string-name>. <article-title>Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study</article-title>. <source xml:lang="en">Eur J Heart Fail</source>
<year>2012</year>; <volume>14</volume>: <fpage>367</fpage>&#x02013;<lpage>376</lpage>.<pub-id pub-id-type="pmid">22298637</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ehf212516-cit-0031">
<string-name>
<surname>Neal</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Perkovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>de Zeeuw</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fulcher</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Erondu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Desai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matthews</surname>
<given-names>DR</given-names>
</string-name>, 
<collab collab-type="authors">Group CPC</collab>
. <article-title>Canagliflozin and cardiovascular and renal events in type 2 diabetes</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2017</year>; <volume>377</volume>: <fpage>644</fpage>&#x02013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">28605608</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ehf212516-cit-0032">
<string-name>
<surname>Wanner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Lachin</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fitchett</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>von Eynatten</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mattheus</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Johansen</surname>
<given-names>OE</given-names>
</string-name>, <string-name>
<surname>Woerle</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Broedl</surname>
<given-names>UC</given-names>
</string-name>, <string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, 
<collab collab-type="authors">Investigators E&#x02010;RO</collab>
. <article-title>Empagliflozin and progression of kidney disease in type 2 diabetes</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2016</year>; <volume>375</volume>: <fpage>323</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">27299675</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ehf212516-cit-0033">
<collab collab-type="authors">Decode Study Group tEDEG</collab>
. <article-title>Glucose tolerance and cardiovascular mortality: comparison of fasting and 2&#x02009;h diagnostic criteria</article-title>. <source xml:lang="en">Arch Intern Med</source>
<year>2001</year>; <volume>161</volume>: <fpage>397</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">11176766</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ehf212516-cit-0034">
<collab collab-type="authors">Decode Study Group EDEG</collab>
. <article-title>Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?</article-title>
<source xml:lang="en">Diabetes Care</source>
<year>2003</year>; <volume>26</volume>: <fpage>688</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">12610023</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ehf212516-cit-0035">
<string-name>
<surname>Lang</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Badano</surname>
<given-names>LP</given-names>
</string-name>, <string-name>
<surname>Mor&#x02010;Avi</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Afilalo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ernande</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Flachskampf</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Foster</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Kuznetsova</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lancellotti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Muraru</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Picard</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Rietzschel</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Rudski</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Tsang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Voigt</surname>
<given-names>JU</given-names>
</string-name>. <article-title>Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title>. <source xml:lang="en">Eur Heart J Cardiovasc Imaging</source>
<year>2015</year>; <volume>16</volume>: <fpage>233</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">25712077</pub-id></mixed-citation></ref><ref id="ehf212516-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ehf212516-cit-0036">
<collab collab-type="authors">Summary of Recommendation Statements</collab>
. <article-title>&#x02009;
<italic>Kidney Int Suppl (2011)</italic>
</article-title>. <year>2013</year>;<volume>3</volume>:<fpage>5</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref></ref-list></back></article>